A research team shows how signaling by an immune system component called interleukin-6 (IL-6) appears to play an important role in driving aggressive, therapy-resistant prostate cancer.
A research team shows how signaling by an immune system component called interleukin-6 (IL-6) appears to play an important role in driving aggressive, therapy-resistant prostate cancer.
Share this Article
Recommended